Yoshida sarcoma is a rare and aggressive type of soft tissue cancer, specifically a malignant mesenchymal tumor, which was initially reported in Japan and typically occurs in children and young adults, often associated with a poor prognosis due to its rapid growth and high metastatic potential.
A connective tissue neoplasm formed by proliferation of mesodermal cells; it is usually highly malignant.
A malignant tumor of the bone which always arises in the medullary tissue, occurring more often in cylindrical bones. The tumor occurs usually before the age of 20, about twice as frequently in males as in females.
A malignant neoplasm arising from tenosynovial tissue of the joints and in synovial cells of tendons and bursae. The legs are the most common site, but the tumor can occur in the abdominal wall and other trunk muscles. There are two recognized types: the monophasic (characterized by sheaths of monotonous spindle cells) and the biphasic (characterized by slit-like spaces or clefts within the tumor, lined by cuboidal or tall columnar epithelial cells). These sarcomas occur most commonly in the second and fourth decades of life. (From Dorland, 27th ed; DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1363)
A multicentric, malignant neoplastic vascular proliferation characterized by the development of bluish-red cutaneous nodules, usually on the lower extremities, most often on the toes or feet, and slowly increasing in size and number and spreading to more proximal areas. The tumors have endothelium-lined channels and vascular spaces admixed with variably sized aggregates of spindle-shaped cells, and often remain confined to the skin and subcutaneous tissue, but widespread visceral involvement may occur. Kaposi's sarcoma occurs spontaneously in Jewish and Italian males in Europe and the United States. An aggressive variant in young children is endemic in some areas of Africa. A third form occurs in about 0.04% of kidney transplant patients. There is also a high incidence in AIDS patients. (From Dorland, 27th ed & Holland et al., Cancer Medicine, 3d ed, pp2105-7) HHV-8 is the suspected cause.
Experimentally induced tumors of the LIVER.
Group of alpharetroviruses (ALPHARETROVIRUS) producing sarcomata and other tumors in chickens and other fowl and also in pigeons, ducks, and RATS.
Experimentally induced neoplasms of CONNECTIVE TISSUE in animals to provide a model for studying human SARCOMA.
Sarcoma 180 is an undifferentiated, transplantable mouse tumor model originally induced by methylcholanthrene, widely used in preclinical cancer research for evaluating efficacy of potential therapeutic agents.
A group of replication-defective viruses, in the genus GAMMARETROVIRUS, which are capable of transforming cells, but which replicate and produce tumors only in the presence of Murine leukemia viruses (LEUKEMIA VIRUS, MURINE).
General ill health, malnutrition, and weight loss, usually associated with chronic disease.
Experimental transplantation of neoplasms in laboratory animals for research purposes.
Experimentally induced new abnormal growth of TISSUES in animals to provide models for studying human neoplasms.
Accumulation or retention of free fluid within the peritoneal cavity.
Neoplasms of whatever cell type or origin, occurring in the extraskeletal connective tissue framework of the body including the organs of locomotion and their various component structures, such as nerves, blood vessels, lymphatics, etc.
Connective tissue tumors, affecting primarily fowl, that are usually caused by avian sarcoma viruses.

CHS 828, a novel pyridyl cyanoguanidine with potent antitumor activity in vitro and in vivo. (1/84)

A new class of recently discovered antineoplastic agents, the pyridyl cyanoguanidines, exert a potent antitumor activity in rodents after oral administration. Optimization in vitro and in vivo has resulted in the selection of the lead candidate CHS 828 (N-(6-chlorophenoxyhexyl)-N'cyano-N"-4-pyridylguanidine). CHS 828 was found to exert potent cytotoxic effects in human breast and lung cancer cell lines, with lesser effects on normal fibroblasts and endothelial cells. In a study using a panel of cell lines with different resistance patterns, the effects of CHS 828 showed a low correlation with the activity patterns of known anticancer agents, and no sensitivity to known mechanisms of multidrug resistance was observed. In nude mice bearing human tumor xenografts, CHS 828, at doses from 20 to 50 mg/kg/day p.o., inhibited the growth of MCF-7 breast cancer tumors and caused regression of NYH small cell lung cancer tumors. Oral administration of CHS 828 once weekly improved efficacy without increasing toxicity. CHS 828 was found to compare favorably with established chemotherapeutic agents such as cyclophosphamide, etoposide, methotrexate, and paclitaxel. In mice with NYH tumors, long-term survival (>6 months) was observed after treatment with CHS 828 was stopped. In conclusion, CHS 828 is an effective new antitumor agent, with a potentially new mechanism of action. CHS 828 is presently being tested in Phase I clinical trials in collaboration with the European Organization for Research and Treatment of Cancer.  (+info)

Metastasis formation of Yoshida sarcoma heterotransplanted in adult golden hamsters treated with anti-hamster thymocyte serum. (2/84)

Growth of Yoshida sarcoma cells heterotransplanted in adult golden hamsters treated with antithymocyte serum was investigated. Control animals were grafted with or without hydrocoritisone conditioning. In the antithymocyte serum-treated group, tumors were produced in cheek pouches and grew progressively in size until Day 21 with no sign of regression. Little host reaction was noticed histologically around the tumor grafts throughout the course. Distant metastases were revealed at autopsy in 9 of 12 animals from Day 14 of inoculation on, and all the experimental animals died by Day 23. Six of the 9 hamsters with metastases died of tumor. By means of the back-transplantation test, the metastatic tumor cells were shown to be consistent with Yoshida sarcoma cells. In hydrocortisone-treated and untreated groups, the tumor size reached a maximum on Day 21 and Day 5, respectively, and then regression followed. No metastasis was detected in either control group.  (+info)

Interleukin-15 antagonizes muscle protein waste in tumour-bearing rats. (3/84)

Tissue protein hypercatabolism (TPH) is an important feature in cancer cachexia, particularly with regard to the skeletal muscle. The Yoshida AH-130 rat ascites hepatoma is a model system for studying the mechanisms involved in the processes that lead to tissue depletion, since it induces in the host a rapid and progressive muscle wasting, primarily due to TPH. The present study was aimed at investigating if IL-15, which is known to favour muscle fibre hypertrophy, could antagonize the enhanced muscle protein breakdown in this cancer cachexia model. Indeed, IL-15 treatment partly inhibited skeletal muscle wasting in AH-130-bearing rats by decreasing (8-fold) protein degradative rates (as measured by 14C-bicarbonate pre-loading of muscle proteins) to values even lower than those observed in non-tumour-bearing animals. These alterations in protein breakdown rates were associated with an inhibition of the ATP-ubiquitin-dependent proteolytic pathway (35% and 41% for 2.4 and 1.2 kb ubiquitin mRNA, and 57% for the C8 proteasome subunit, respectively). The cytokine did not modify the plasma levels of corticosterone and insulin in the tumour hosts. The present data give new insights into the mechanisms by which IL-15 exerts its preventive effect on muscle protein wasting and seem to warrant the implementation of experimental protocols involving the use of the cytokine in the treatment of pathological states characterized by TPH, particularly in skeletal muscle, such as in the present model of cancer cachexia.  (+info)

Day-night pattern of energy expenditure and body temperature in cachectic tumour-bearing rats. (4/84)

The implication of an increase in energy expenditure in cancer cachexia, which seems to be related to the type of tumour, remains unclear. We therefore investigated the energy metabolism and body temperature in anorectic and cachectic rats bearing the Yoshida sarcoma (TB), in comparison with pair-fed (PF) and ad-libitum fed (AL) control rats. The resting energy expenditure was higher in the TB than in the two control groups when corrected for the modifications of body composition. However, the total energy expenditure did not differ between the TB and the AL, presumably because of the drop of activity in TB. There was a temporal distribution of differences in energy expenditure with higher energy expenditure in TB than in AL during the diurnal phase and a lack of difference during the nocturnal phase. The TB presented a fever, which was limited to the diurnal period. Moreover, the acrophase of the body temperature rhythm was delayed in the TB. These results highlight the circadian effects of tumour development on the energy metabolism of the host and hint to the possible implication of cytokines.  (+info)

Tissue distribution and biotransformation of potassium oxonate after oral administration of a novel antitumor agent (drug combination of tegafur, 5-chloro-2,4-dihydroxypyridine, and potassium oxonate) to rats. (5/84)

S-1, a new oral 5-fluorouracil (5-FU)-derivative antitumor agent, is composed of tegafur, 5-chloro-2,4-dihydropyridine, and potassium oxonate (Oxo). Oxo, which inhibits the phosphorylation of 5-FU, is added to reduce the gastrointestinal (GI) toxicity of the agent. In this study, we investigated the tissue distribution and the metabolic fate of Oxo in rats after oral administration of S-1. Oxo was mainly distributed to the intracellular sites of the small intestines in a much higher concentration than 5-FU, but little distributed to other tissues, including tumorous ones in which 5-FU was observed after oral administration of S-1. Plasma concentration-time profiles of Oxo and its metabolites after i.v. and oral administration of S-1 revealed that Oxo was mainly converted to cyanuric acid in the GI tract. Furthermore, the analysis of drug-related radioactivity in GI contents and in vitro studies suggested that Oxo was converted to cyanuric acid by two routes, the first being direct conversion by the gut flora in the cecum, and the second, conversion by xanthine oxidase or perhaps by aldehyde oxidase after degradation to 5-azauracil (5-AZU) by the gastric acid. These results indicate that, although a part of the administered Oxo was degraded in the GI tract, Oxo was mainly distributed to the intracellular sites of the small intestines in a much higher concentration than 5-FU and that little was distributed to other tissues, including tumors. We conclude that this is the reason why Oxo suppresses the GI toxicity of 5-FU without affecting its antitumor activity.  (+info)

DNA synthesis in tumor-bearing rats. (6/84)

Thmidine (TdR) incorporation into DNA increased in the livers and spleens of rats bearing Yoshida sarcoma (solid type) or AH130 (solid type). TdR kinase and DNA polymerase activities increased in the serum, liver, and spleen of these rats, while thymidine monophosphate kinase activity increased appreciably only in the liver and spleen. On diethylaminoethyl cellulose column chromatography, 2 peaks of TdR dinase activity were separated from the serum and tumor tissues of rats bearing Yoshida sarcoma (solid type) while only 1 peak was obtained from the liver. TdR kinase activity in the serum decreased abruptly 7 hr after removal of the Yoshida sarcoma, while that in the liver decreased more slowly.  (+info)

D-24851, a novel synthetic microtubule inhibitor, exerts curative antitumoral activity in vivo, shows efficacy toward multidrug-resistant tumor cells, and lacks neurotoxicity. (7/84)

N-(pyridin-4-yl)-[1-(4-chlorbenzyl)-indol-3-yl]-glyoxyl-amid (D-24851) is a novel synthetic compound that was identified in a cell-based screening assay to discover cytotoxic drugs. D-24851 destabilizes microtubules and blocks cell cycle transition specifically at G2-M phase. The binding site of D-24851 does not overlap with the tubulin binding sites of known microtubule-destabilizing agents like vincristine or colchicine. In vitro, D-24851 has potent cytotoxic activity toward a panel of established human tumor cell lines including SKOV3 ovarian cancer, U87 glioblastoma, and ASPC-1 pancreatic cancer cells. In vivo, oral D-24851 treatment induced complete tumor regressions (cures) in rats bearing Yoshida AH13 sarcomas. Of importance is that the administration of curative doses of D-24851 to the animals revealed no systemic toxicity in terms of body weight loss and neurotoxicity in contrast to the administration of paclitaxel or vincristine. Interestingly, multidrug-resistant cell lines generated by vincristine-driven selection or transfection with the Mr 170,000 P-glycoprotein encoding cDNA were rendered resistant toward paclitaxel, vincristine, or doxorubicin but not towards D-24851 when compared with the parental cells. Because of its synthetic nature, its oral applicability, its potent in vitro and in vivo antitumoral activity, its efficacy against multidrug-resistant tumors, and the lack of neurotoxicity, D-24851 may have significant potential for the treatment of various malignancies.  (+info)

Intracellular distribution of various enzymes concerned with DNA synthesis from normal and regenerating rat liver, and Yoshida sarcoma. (8/84)

During the fractionation of various enzymes concerned with DNA synthesis from the postmicrosomal supernatant fraction of various tissues, DNA polymerace [EC 2.7.7.7], thymidine kinase [EC 2.7.1.75], dTMP kinase [EC 2.7.4.9], deoxycytidine kinase [EC 2.7.1.74], and deoxycytidine monophosphokinase (dCMP kinase) [EC 2.7.4.14] were found in the pellet fraction of postmicrosomal supernatant. Further, the uridine kinase [EC 2.7.1.48] and aspartate transcarbamylase [EC 2.1.3.2] activities of postmicrosomal supernatant from various tissues were also present in this pellet fraction. The activities of DNA polymerase, thymidine kinase, uridine kinase, and aspartate transcarbamylase from normal and regenerating rat liver, and Yoshida sarcoma were higher in the pellet fraction than in the supernatant. On the other hand, the activities of dTMP kinase, dCMP kinase, and orotidine-5'-phosphate decarboxylase [EC 4.1.1.23] were lower in the pellet fraction than in the supernatant. The pellet fractions of regenerating rat liver and Yoshida sarcoma showed a remarkable incorporation of various precursors (thymidine, dTMP, deoxycytidine, and dCMP) into DNA in the presence of a suitable DNA template, ATP and all four deoxynucleoside 5'-triphosphates for DNA synthesis. Normal adult rat liver catalyzed a much smaller incorporation of all these precursors, except for dCMP.  (+info)

I'm sorry for the confusion, but "Sarcoma, Yoshida" is not a recognized medical term or a specific type of sarcoma in any major oncology reference or database. It appears that "Yoshida" might be referring to a person who described or studied a particular type of sarcoma. However, I cannot find any relevant information related to this exact term.

Sarcomas are cancers that develop from connective tissues such as bones, muscles, tendons, cartilages, nerves, and blood vessels. They can be categorized into two main groups: bone sarcomas and soft tissue sarcomas. There are many subtypes of sarcoma, each with its unique features, diagnostic criteria, and treatment approaches.

If you have more context or information about "Sarcoma, Yoshida," I would be happy to help you further research the topic. However, based on the available data, it is not possible to provide a medical definition for this term.

Sarcoma is a type of cancer that develops from certain types of connective tissue (such as muscle, fat, fibrous tissue, blood vessels, or nerves) found throughout the body. It can occur in any part of the body, but it most commonly occurs in the arms, legs, chest, and abdomen.

Sarcomas are classified into two main groups: bone sarcomas and soft tissue sarcomas. Bone sarcomas develop in the bones, while soft tissue sarcomas develop in the soft tissues of the body, such as muscles, tendons, ligaments, fat, blood vessels, and nerves.

Sarcomas can be further classified into many subtypes based on their specific characteristics, such as the type of tissue they originate from, their genetic makeup, and their appearance under a microscope. The different subtypes of sarcoma have varying symptoms, prognoses, and treatment options.

Overall, sarcomas are relatively rare cancers, accounting for less than 1% of all cancer diagnoses in the United States each year. However, they can be aggressive and may require intensive treatment, such as surgery, radiation therapy, and chemotherapy.

Ewing sarcoma is a type of cancer that originates in bones or the soft tissues surrounding them, such as muscles and tendons. It primarily affects children and adolescents, although it can occur in adults as well. The disease is characterized by small, round tumor cells that typically grow quickly and are prone to metastasize (spread) to other parts of the body, most commonly the lungs, bones, and bone marrow.

Ewing sarcoma is caused by a genetic abnormality, specifically a chromosomal translocation that results in the fusion of two genes, EWSR1 and FLI1. This gene fusion leads to the formation of an abnormal protein that disrupts normal cell growth and division processes, ultimately resulting in cancer.

Symptoms of Ewing sarcoma can vary depending on the location and size of the tumor but may include pain or swelling in the affected area, fever, fatigue, and weight loss. Diagnosis typically involves imaging studies such as X-rays, CT scans, or MRI scans to locate the tumor, followed by a biopsy to confirm the presence of cancer cells. Treatment may involve surgery, radiation therapy, chemotherapy, or a combination of these approaches, depending on the stage and location of the disease.

Synovial sarcoma is a rare type of cancer that typically develops in the soft tissues surrounding the joints, such as the synovial membrane, which lines the joint capsules. Despite its name, synovial sarcoma does not necessarily arise from the synovium. It is called so due to its resemblance to this tissue under a microscope.

This form of sarcoma primarily affects young adults and can be found in various parts of the body, but it most commonly occurs in the extremities, particularly near the knees. Synovial sarcoma is characterized by specific genetic changes that result in the formation of fusion proteins, which contribute to uncontrolled cell growth and tumor development.

There are two main subtypes of synovial sarcoma: monophasic and biphasic. Monophasic synovial sarcoma is composed of either spindle-shaped (spaghetti-like) cells or epithelioid (roundish) cells, while biphasic synovial sarcoma contains both types of cells. A third subtype, called poorly differentiated synovial sarcoma, has a more aggressive behavior and is composed of small round cells that do not resemble the typical spindle or epithelioid cells.

Treatment for synovial sarcoma usually involves surgical removal of the tumor, often followed by radiation therapy and/or chemotherapy to reduce the risk of recurrence and metastasis. The prognosis varies depending on factors such as the size and location of the tumor, the patient's age, and the presence of metastases at diagnosis.

Kaposi sarcoma (KS) is a type of cancer that causes abnormal growths in the skin, lymph nodes, or other organs. It is caused by the Kaposi sarcoma-associated herpesvirus (KSHV), also known as human herpesvirus 8 (HHV8). There are several forms of KS, including:

1. Classic KS: This form primarily affects older men of Mediterranean, Middle Eastern, or Ashkenazi Jewish descent. It tends to progress slowly and mainly involves the skin.
2. Endemic KS: Found in parts of Africa, this form predominantly affects children and young adults, regardless of their HIV status.
3. Immunosuppression-associated KS: This form is more aggressive and occurs in people with weakened immune systems due to organ transplantation or other causes.
4. Epidemic KS (AIDS-related KS): This is the most common form of KS, seen primarily in people with HIV/AIDS. The widespread use of antiretroviral therapy (ART) has significantly reduced its incidence.

KS lesions can appear as red, purple, or brown spots on the skin and may also affect internal organs such as the lungs, lymph nodes, or gastrointestinal tract. Symptoms vary depending on the location of the lesions but often include fever, fatigue, weight loss, and swelling in the legs or abdomen. Treatment options depend on the extent and severity of the disease and may involve local therapies (e.g., radiation, topical treatments), systemic therapies (e.g., chemotherapy, immunotherapy), or a combination of these approaches.

Experimental liver neoplasms refer to abnormal growths or tumors in the liver that are intentionally created or manipulated in a laboratory setting for the purpose of studying their development, progression, and potential treatment options. These experimental models can be established using various methods such as chemical induction, genetic modification, or transplantation of cancerous cells or tissues. The goal of this research is to advance our understanding of liver cancer biology and develop novel therapies for liver neoplasms in humans. It's important to note that these experiments are conducted under strict ethical guidelines and regulations to minimize harm and ensure the humane treatment of animals involved in such studies.

Avian sarcoma viruses (ASVs) are a group of retroviruses that primarily infect birds and cause various types of tumors, particularly sarcomas. These viruses contain an oncogene, which is a gene that has the ability to transform normal cells into cancerous ones. The oncogene in ASVs is often derived from cellular genes called proto-oncogenes, which are normally involved in regulating cell growth and division.

ASVs can be divided into two main types: non-defective and defective. Non-defective ASVs contain a complete set of viral genes that allow them to replicate independently, while defective ASVs lack some of the necessary viral genes and require assistance from other viruses to replicate.

One well-known example of an avian sarcoma virus is the Rous sarcoma virus (RSV), which was first discovered in chickens by Peyton Rous in 1910. RSV causes a highly malignant form of sarcoma in chickens and has been extensively studied as a model system for cancer research. The oncogene in RSV is called v-src, which is derived from the normal cellular gene c-src.

Avian sarcoma viruses have contributed significantly to our understanding of the molecular mechanisms underlying cancer development and have provided valuable insights into the role of oncogenes in tumorigenesis.

I'm sorry for any confusion, but "Sarcoma, Experimental" is not a recognized medical term or definition. Sarcomas are a type of cancer that develop in the body's connective tissues, such as bones, muscles, tendons, cartilage, and fat. There are many different types of sarcomas, classified based on the specific type of tissue they originate from.

Experimental, on the other hand, refers to something that is being tested or tried out for the first time, typically as part of a scientific experiment or clinical trial. In the context of cancer treatment, an experimental therapy might refer to a new drug, procedure, or device that is still being studied in clinical trials to determine its safety and effectiveness.

Therefore, "Sarcoma, Experimental" could potentially refer to a clinical trial or research study involving a new treatment for sarcoma, but it would not be a medical definition in and of itself. If you have any specific questions about sarcomas or experimental treatments, I would recommend consulting with a healthcare professional or medical researcher for more accurate information.

I'm sorry for any confusion, but "Sarcoma 180" is not a recognized medical term or an official classification of sarcomas in humans. It appears to be a term used primarily in research involving mice. Sarcoma 180 is a transplantable tumor that was first isolated from a mouse and has been used as a model for cancer research, particularly in studies involving immunotherapy and cancer treatment.

In general, sarcomas are cancers that develop from connective tissues such as bones, muscles, tendons, cartilages, nerves, and blood vessels. They can be further classified into various subtypes based on the specific type of tissue they originate from and their genetic characteristics. If you have any concerns about a specific medical condition or term, I would recommend consulting with a healthcare professional for accurate information.

Sarcoma viruses, murine, are a group of RNA viruses that primarily affect mice and other rodents. They are classified as type C retroviruses, which means they contain an envelope, have reverse transcriptase enzyme activity, and replicate through a DNA intermediate.

The murine sarcoma viruses (MSVs) are associated with the development of various types of tumors in mice, particularly fibrosarcomas, which are malignant tumors that originate from fibroblasts, the cells that produce collagen and other fibers in connective tissue.

The MSVs are closely related to the murine leukemia viruses (MLVs), and together they form a complex called the murine leukemia virus-related viruses (MLVRVs). The MLVRVs can undergo recombination events, leading to the generation of new viral variants with altered biological properties.

The MSVs are important tools in cancer research because they can transform normal cells into tumor cells in vitro and in vivo. The study of these viruses has contributed significantly to our understanding of the molecular mechanisms underlying cancer development and progression.

Cachexia is a complex metabolic disorder characterized by severe weight loss, muscle wasting, and weakness. It is often associated with chronic diseases such as cancer, HIV/AIDS, heart failure, kidney disease, and chronic obstructive pulmonary disease (COPD). Cachexia differs from simple malnutrition or starvation in that it involves a significant loss of muscle mass and an imbalance in energy metabolism, even when adequate calories are consumed.

The hallmark features of cachexia include:

1. Weight loss: Unintentional loss of more than 5% of body weight over 12 months or less, or more than 2% in individuals already underweight.
2. Muscle wasting: Reduction in skeletal muscle mass and strength, leading to weakness and functional impairment.
3. Fatigue and anorexia: Decreased appetite and reduced food intake due to various factors such as inflammation, hormonal imbalances, and psychological distress.
4. Inflammation: Elevated levels of pro-inflammatory cytokines (e.g., TNF-α, IL-1, IL-6) that contribute to metabolic dysregulation and muscle wasting.
5. Insulin resistance: Impaired glucose uptake and utilization by cells, leading to increased blood glucose levels and altered energy metabolism.
6. Altered protein metabolism: Increased protein breakdown and decreased protein synthesis in skeletal muscles, contributing to muscle wasting.
7. Altered lipid metabolism: Increased lipolysis (breakdown of fat) and impaired lipogenesis (formation of fat), leading to loss of adipose tissue and altered energy storage.

Cachexia significantly impacts patients' quality of life, treatment outcomes, and overall survival. Currently, there is no single effective treatment for cachexia, and management typically involves addressing the underlying disease, nutritional support, exercise interventions, and pharmacological therapies to target specific aspects of the metabolic dysregulation associated with this condition.

Neoplasm transplantation is not a recognized or established medical procedure in the field of oncology. The term "neoplasm" refers to an abnormal growth of cells, which can be benign or malignant (cancerous). "Transplantation" typically refers to the surgical transfer of living cells, tissues, or organs from one part of the body to another or between individuals.

The concept of neoplasm transplantation may imply the transfer of cancerous cells or tissues from a donor to a recipient, which is not a standard practice due to ethical considerations and the potential harm it could cause to the recipient. In some rare instances, researchers might use laboratory animals to study the transmission and growth of human cancer cells, but this is done for scientific research purposes only and under strict regulatory guidelines.

In summary, there is no medical definition for 'Neoplasm Transplantation' as it does not represent a standard or ethical medical practice.

Experimental neoplasms refer to abnormal growths or tumors that are induced and studied in a controlled laboratory setting, typically in animals or cell cultures. These studies are conducted to understand the fundamental mechanisms of cancer development, progression, and potential treatment strategies. By manipulating various factors such as genetic mutations, environmental exposures, and pharmacological interventions, researchers can gain valuable insights into the complex processes underlying neoplasm formation and identify novel targets for cancer therapy. It is important to note that experimental neoplasms may not always accurately represent human cancers, and further research is needed to translate these findings into clinically relevant applications.

Ascites is an abnormal accumulation of fluid in the peritoneal cavity, which is the space between the lining of the abdominal wall and the organs within it. This buildup of fluid can cause the belly to swell and become distended. Ascites can be caused by various medical conditions, including liver cirrhosis, cancer, heart failure, and kidney disease. The accumulation of fluid in the peritoneal cavity can lead to complications such as infection, reduced mobility, and difficulty breathing. Treatment for ascites depends on the underlying cause and may include diuretics, paracentesis (a procedure to remove excess fluid from the abdomen), or treatment of the underlying medical condition.

Soft tissue neoplasms refer to abnormal growths or tumors that develop in the soft tissues of the body. Soft tissues include muscles, tendons, ligaments, fascia, nerves, blood vessels, fat, and synovial membranes (the thin layer of cells that line joints and tendons). Neoplasms can be benign (non-cancerous) or malignant (cancerous), and their behavior and potential for spread depend on the specific type of neoplasm.

Benign soft tissue neoplasms are typically slow-growing, well-circumscribed, and rarely spread to other parts of the body. They can often be removed surgically with a low risk of recurrence. Examples of benign soft tissue neoplasms include lipomas (fat tumors), schwannomas (nerve sheath tumors), and hemangiomas (blood vessel tumors).

Malignant soft tissue neoplasms, on the other hand, can grow rapidly, invade surrounding tissues, and may metastasize (spread) to distant parts of the body. They are often more difficult to treat than benign neoplasms and require a multidisciplinary approach, including surgery, radiation therapy, and chemotherapy. Examples of malignant soft tissue neoplasms include sarcomas, such as rhabdomyosarcoma (arising from skeletal muscle), leiomyosarcoma (arising from smooth muscle), and angiosarcoma (arising from blood vessels).

It is important to note that soft tissue neoplasms can occur in any part of the body, and their diagnosis and treatment require a thorough evaluation by a healthcare professional with expertise in this area.

I'm sorry for any confusion, but "Avian Sarcoma" is not a widely recognized medical term. The term "sarcoma" is used in pathology to describe a type of cancer that develops from certain types of connective tissue (such as bone, cartilage, muscle, or blood vessels).

On the other hand, "avian" refers to birds or related to birds. In medical literature, avian sarcomas are sometimes used to describe sarcomas that occur in birds. However, specific types of avian sarcomas would be defined by the type of cell from which they originate (like a fibrosarcoma, osteosarcoma, etc.).

If you're asking about a specific medical condition or context, could you please provide more details? I'm here to help!

Lee SY, Obata Y, Yoshida M, et al. (2003). "Immunomic analysis of human sarcoma". Proc. Natl. Acad. Sci. U.S.A. 100 (5): 2651-6 ...
Lee SY, Obata Y, Yoshida M, et al. (2003). "Immunomic analysis of human sarcoma". Proc. Natl. Acad. Sci. U.S.A. 100 (5): 2651-6 ...
Lee SY, Obata Y, Yoshida M, et al. (2003). "Immunomic analysis of human sarcoma". Proc. Natl. Acad. Sci. U.S.A. 100 (5): 2651-6 ...
Lee SY, Obata Y, Yoshida M, et al. (2003). "Immunomic analysis of human sarcoma". Proc. Natl. Acad. Sci. U.S.A. 100 (5): 2651-6 ...
Orengo, Christine Anne (1977). Disruption of iron metabolism in rats with Yoshida sarcomas (MSc thesis). University of Aberdeen ... degree in Medical Physics in 1977 for research on the disruption of iron metabolism in laboratory rats with Yoshida sarcomas. ...
Ewing sarcoma breakpoint region 1 on the Atlas of Genetics and Oncology (Articles with short description, Short description is ... Bhagirath T, Abe S, Nojima T, Yoshida MC (1995). "Molecular analysis of a t(11;22) translocation junction in a case of Ewing's ... Ban J, Siligan C, Kreppel M, Aryee D, Kovar H (2006). "Ews-Fli1 in Ewing's Sarcoma: Real Targets and Collateral Damage". New ... "Entrez Gene: EWSR1 Ewing sarcoma breakpoint region 1". Flucke U, van Noesel MM, Siozopoulou V, Creytens D, Tops BB, van Gorp JM ...
"Isolation of genes differentially expressed between the Yoshida sarcoma and long-survival Yoshida sarcoma variants: Origin of ... In 1943, Yoshida found a cancer cell line, so-called Yoshida Sarcoma, and experimentally proved that cancer is generated from ... Tomizo Yoshida (吉田 富三, Yoshida Tomizō, 1903-1973) was a prominent Japanese pathologist, famous for discovering the Yoshida ... Tomizo Yoshida(in Japanese) Robert Koch Gold Medal 日本癌学会 吉田富三賞(吉田賞) Tomizo Yoshida Award (in Japanese) 山際−吉
Research on Yoshida Sarcoma, a strain of tumor cells, was also conducted at this institute in the 1950s. Takaoki Sasaki (1939 ... published in 1932 by Takaoki Sasaki and Tomizo Yoshida, was the first scientific report in the world on a successful method for ... 1953) Tomizo Yoshida (1953 - 1973) Hirooki Sasaki (1973 - 1990) Motomichi Sasaki (1990 - 1995) Yoshiyuki Hashimoto (1995 - 2001 ...
... inhibits growth of Gram-positive bacteria, leukemia L-1210 in mice and Yoshida rat sarcoma cells in tissue ...
Lee SY, Obata Y, Yoshida M, Stockert E, Williamson B, Jungbluth AA, Chen YT, Old LJ, Scanlan MJ (Mar 2003). "Immunomic analysis ... of human sarcoma". Proceedings of the National Academy of Sciences of the United States of America. 100 (5): 2651-2656. Bibcode ...
Matsumoto Y, Imai Y, Lu Yoshida N, Sugita Y, Tanaka T, Tsujimoto G, Saito H, Oshida T (Aug 2004). "Upregulation of the ... "Immunomic analysis of human sarcoma". Proceedings of the National Academy of Sciences of the United States of America. 100 (5 ... Lee SY, Obata Y, Yoshida M, Stockert E, Williamson B, Jungbluth AA, Chen YT, Old LJ, Scanlan MJ (Mar 2003). " ...
"Uncommon and peculiar soft tissue sarcomas: Multidisciplinary review and practical recommendations. Spanish Group for Sarcoma ... Ogura, Koichi; Fujiwara, Tomohiro; Beppu, Yasuo; Chuman, Hirokazu; Yoshida, Akihiko; Kawano, Hirotaka; Kawai, Akira (2012-06-08 ... As with all these subgroups of sarcomas, standard treatment for primary EMC is complete surgical resection, in high risk cases ... "The Ewing's sarcoma protein interacts with the Tudor domain of the survival motor neuron protein". Molecular Brain Research. ...
Sarcoma 180, NF-sarcoma, and Yoshida sarcoma. Furukawa, M.; Hayakawa, I.; Ohta, G.; Iitaka, Y. (1 January 1971). "Structure and ...
... has been shown to exhibit activity against Yoshida sarcoma in rats, leukemia P388, sarcoma 180, Ehrlich Ascites ...
Mataro Nagayo, pathologist Takaoki Sasaki, oncologist Masaru Kuru, surgeon Tomizo Yoshida, discoverer of Yoshida Sarcoma ... 1983: Mitsuaki Yoshida identified the molecular structure of human T-lymphotropic virus 1 responsible for adult T-cell leukemia ... Sarcoma Center, Palliative Therapy, General Medicine, Anesthesiology/Pain Service, Psycho-Oncology, Plastic and Reconstructive ...
Satoh H, Yoshida MC, Matsushime H, Shibuya M, Sasaki M (August 1987). "Regional localization of the human c-ros-1 on 6q22 and ... Matsushime H, Wang LH, Shibuya M (August 1986). "Human c-ros-1 gene homologous to the v-ros sequence of UR2 sarcoma virus ... Matsushime H, Wang LH, Shibuya M (August 1986). "Human c-ros-1 gene homologous to the v-ros sequence of UR2 sarcoma virus ... "Entrez Gene: ROS1 v-ros UR2 sarcoma virus oncogene homolog 1 (avian)". Berge EM, Doebele RC (February 2014). "Targeted ...
Taira M, Yoshida T, Miyagawa K, Sakamoto H, Terada M, Sugimura T (May 1987). "cDNA sequence of human transforming gene hst and ... "Entrez Gene: FGF4 fibroblast growth factor 4 (heparin secretory transforming protein 1, Kaposi sarcoma oncogene)". Feldman B, ... Yoshida T, Miyagawa K, Odagiri H, Sakamoto H, Little PF, Terada M, Sugimura T (Oct 1987). "Genomic sequence of hst, a ... Wada A, Sakamoto H, Katoh O, Yoshida T, Yokota J, Little PF, Sugimura T, Terada M (Dec 1988). "Two homologous oncogenes, HST1 ...
Semba K, Yamanashi Y, Nishizawa M, Sukegawa J, Yoshida M, Sasaki M, Yamamoto T, Toyoshima K (Mar 1985). "Location of the c-yes ... "Entrez Gene: YES1 v-yes-1 Yamaguchi sarcoma viral oncogene homolog 1". Fuhrer, D K; Yang Y C (Jul 1996). "Complex formation of ... This gene is the cellular homolog of the Yamaguchi sarcoma virus oncogene. The encoded protein has tyrosine kinase activity and ...
In a study done by Yoshida and Kikuchi, routes of glycine breakdown were measured. Glycine can be converted into serine and ... Serine dehydratase has also been found to be absent in human colon carcinoma and rat sarcoma. The observed enzyme imbalance in ... This pattern is found in sarcomas and carcinomas, and in tumors of human and rodent origin. Human and rat serine dehydratase ... "Enzymic imbalance in serine metabolism in human colon carcinoma and rat sarcoma". British Journal of Cancer. 57 (1): 87-90. doi ...
Two variants of a disease associated with ETV4 is Ewing Sarcoma and Extraosseous Ewing's Sarcoma. While both are cancerous ... Nosho K, Yoshida M, Yamamoto H, Taniguchi H, Adachi Y, Mikami M, Hinoda Y, Imai K (May 2005). "Association of Ets-related ... Higashino F, Yoshida K, Fujinaga Y, Kamio K, Fujinaga K (Feb 1993). "Isolation of a cDNA encoding the adenovirus E1A enhancer ... Takahashi A, Higashino F, Aoyagi M, Yoshida K, Itoh M, Kobayashi M, Totsuka Y, Kohgo T, Shindoh M (Feb 2005). "E1AF degradation ...
Yoshida T, Ozawa Y, Kimura T, Sato Y, Kuznetsov G, Xu S, et al. (March 2014). "Eribulin mesilate suppresses experimental ... and various sarcomas. Two new[when?] eribulin based products are in the research and development phase; a liposomal formulation ... "Antimitotic and Non-mitotic Effects of Eribulin Mesilate in Soft Tissue Sarcoma". Anticancer Research. 36 (4): 1553-61. PMID ...
Haro A, Yano T, Kohno M, Yoshida T, Koga T, Okamoto T, et al. (December 2013). "Expression of Brachyury gene is a significant ... and Rare in Other Carcinomas and Sarcomas: An Immunohistochemical Study of 5229 Cases". The American Journal of Surgical ...
Yoshida, Isao; Moro, Hiroshi (February 2016). "Clinicopathologic analysis of TAFRO syndrome demonstrates a distinct subtype of ... "Next-generation sequencing of idiopathic multicentric and unicentric Castleman disease and follicular dendritic cell sarcomas ...
Kaposi's sarcoma-associated herpesvirus (KSHV or HHV-8) is associated with Kaposi's sarcoma, a type of skin cancer. Merkel cell ... Yoshida M, Jeang KT (2005). "Preface to 25 years of HTLV-1 and ATL research". Oncogene. 24 (39): 5925. doi:10.1038/sj.onc. ... Sarcoma of the Common Fowl.)". The Journal of Experimental Medicine. 12 (5): 696-705. doi:10.1084/jem.12.5.696. PMC 2124810. ... 2015). "Kaposi's Sarcoma-Associated Herpesvirus (KSHV) Induces the Oncogenic miR-17-92 Cluster and Down-Regulates TGF-β ...
Okumura E, Fukuhara T, Yoshida H, Hanada Si S, Kozutsumi R, Mori M, et al. (February 2002). "Akt inhibits Myt1 in the ... Bryan BA, Dyson OF, Akula SM (March 2006). "Identifying cellular genes crucial for the reactivation of Kaposi's sarcoma- ...
Horiuchi M, Nakao T, Tsutsumi M, Nakaya Y, Fuseya H, Yoshida M, Yoshimura T, Hayashi Y, Fukushima H, Inoue T, Yamane T (2019 ... Some one-third to one-half of these individuals have a history of Kaposi's sarcoma, less commonly of multicentric Castleman ... Cesarman E, Chang Y, Moore PS, Said JW, Knowles DM (May 1995). "Kaposi's sarcoma-associated herpesvirus-like DNA sequences in ... Cesarman E, Chang Y, Moore PS, Said JW, Knowles DM (May 1995). "Kaposi's sarcoma-associated herpesvirus-like DNA sequences in ...
Yoshida, Z.; Osawa, E. (1971). Aromaticity. Chemical Monograph Series 22. Kyoto: Kagaku-dojin. pp. 174-8. Shinkai S, Ogawa T, ... H. M. Temin and S. Mizutani (1970). "Viral RNA-dependent DNA polymerase in virions of Rous sarcoma virus" (PDF). Nature. 226 ( ... Satoshi Mizutani and Howard Martin Temin jointly discovered that the Rous sarcoma virus particle contained the enzyme reverse ... Shigeru Yoshida Archived 14 March 2023 at the Wayback Machine nobelprize.org Nomination archive - Yoshio Koya Archived 9 ...
August 1995). "Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease". Blood. 86 (4): ... Yoshida, Isao; Moro, Hiroshi; Nikkuni, Koji; Takai, Kazue (2016). "Clinicopathologic analysis of TAFRO syndrome demonstrates a ... Chen KT (April 1984). "Multicentric Castleman's disease and Kaposi's sarcoma". The American Journal of Surgical Pathology. 8 (4 ... describing a multicentric variant of the disease and with some reports describing an association with Kaposi's sarcoma. In 1995 ...
Akisaka, T; Yoshida, H; Suzuki, R; Takama, K (March 2008). "Adhesion structures and their cytoskeleton-membrane interactions at ... In the early 1980s, chicken embryo fibroblasts were transformed using the Rous sarcoma virus (RSV) containing the oncogene v- ...
Yoshida T, Imai T, Kakizaki M, Nishimura M, Takagi S, Yoshie O (June 1998). "Identification of single C motif-1/lymphotactin ... Lüttichau HR, Johnsen AH, Jurlander J, Rosenkilde MM, Schwartz TW (June 2007). "Kaposi sarcoma-associated herpes virus targets ...
Yoshida C, Takeuchi M (2008). "Histiocytic sarcoma: identification of its histiocytic origin using immunohistochemistry". ... Histiocytic sarcoma is a tumor derived from histiocytes. The tumor is often positive for CD163 and can appear in the thyroid. ... De Vos FY, Gerding MN, Arends JW, Wegman JJ (August 2008). "Histiocytic sarcoma localised in the thyroid: a case report". Ann. ... Vos JA, Abbondanzo SL, Barekman CL, Andriko JW, Miettinen M, Aguilera NS (May 2005). "Histiocytic sarcoma: a study of five ...
Ascites tumors : Yoshida sarcoma and ascites hepatoma(s) /. 1964. 9. Assessment of thyroid follicular cell tumors /. 1998. ...
We have identified a novel pathway that directs Lyn/Src family tyrosine kinase signals to the invadopodia to regulate sarcoma ... These data define a novel pathway that directs Lyn/Src family tyrosine kinase signals to sarcoma cell invadopodia through ... Yamaguchi H, Yoshida S, Muroi E, Yoshida N, Kawamura M, Kouchi Z et al. Phosphoinositide 3-kinase signaling pathway mediated by ... Tie, S., McCarthy, D., Kendrick, T. et al. Regulation of sarcoma cell migration, invasion and invadopodia formation by AFAP1L1 ...
Although histone deacetylase (HDAC) inhibitors are known to suppress synovial sarcoma in vitro and in vivo, the exact mechanism ... Finally, restoration of EGR1 or PTEN expression is sufficient to induce synovial sarcoma cell death. Taken together, our ... The SS18-SSX oncoprotein, characteristic of synovial sarcoma, maintains EGR1 expression at low levels, whereas it is ... we show that EGR1 modulation of PTEN contributes to HDAC inhibitor-induced apoptosis in synovial sarcoma. ...
Ewing sarcoma, a highly malignant primary bone tumor that is derived from red bone marrow, was first described by James Ewing ... Tsuji AB, Kato K, Sugyo A, Okada M, Sudo H, Yoshida C, et al. Comparison of 2-amino-[3-¹¹C]isobutyric acid and 2-deoxy-2-[¹⁸F] ... These studies may reveal the classic signs of Ewing sarcoma. The appearance of Ewing sarcoma may vary from that of pure lysis ... Ewings sarcoma and primitive neuroectodermal tumor in adults: are they different from Ewings sarcoma and primitive ...
The analysis confirmed the reliability of NGS RNA-based approaches in detecting sarcoma-specific rearrangements. Overall, the ... The analysis confirmed the reliability of NGS RNA-based approaches in detecting sarcoma-specific rearrangements. Overall, the ... were employed to profile a large set of sarcomas of different histotypes. ... were employed to profile a large set of sarcomas of different histotypes. ...
Kijima Y, Umekita Y, Yoshinaka H, Taguchi S, Owaki T, Funasako Y, Sakamoto A, Yoshida H, Aikou T. Kijima Y, et al. Among ... Stromal sarcoma with features of giant cell malignant fibrous histiocytoma. ...
NKX2.2 is a useful immunohistochemical marker for Ewing sarcoma. Yoshida A, et al. Am J Surg Pathol, 2012 Jul. PMID 22446943 ... inducing Ewing-like sarcomas. Title: Insight into the Etiology of Undifferentiated Soft Tissue Sarcomas from a Novel Mouse ... The Utility of NKX2.2 and TLE1 Immunohistochemistry in the Differentiation of Ewing Sarcoma and Synovial Sarcoma. Title: The ... Usefulness of NKX2.2 Immunohistochemistry for Distinguishing Ewing Sarcoma from Other Sinonasal Small Round Blue Cell Tumors. ...
Asano N, Yoshida A, Ogura K, Kobayashi E, Susa M, Morioka H. et al. Prognostic Value of Relevant Clinicopathologic Variables in ... Lymph node metastasis from soft tissue sarcoma in adults. Analysis of data from a prospective database of 1772 sarcoma patients ... The epidemiology of sarcoma. Clinical sarcoma research. 2012;2:14 2. Levi F, La Vecchia C, Randimbison L, Te VC. Descriptive ... clear cell sarcoma, epithelioid sarcoma, synovial sarcoma) and not only during ILP procedures [26, 29]. ...
2018 - 2021 AIM expression, mutation and function in canine histiocytic sarcoma. *2015 - 2018 The role of canine AIM in ... Hajime Asada, Akiyoshi Tani, Hiroki Sakuma, Miyuki Hirabayashi, Yuki Matsumoto, Kei Watanabe, Masaya Tsuboi, Shino Yoshida, Kei ... Whole exome and transcriptome analysis revealed the activation of ERK and Akt signaling pathway in canine histiocytic sarcoma. ... in a xenograft mouse model of canine histiocytic sarcoma. Veterinary and Comparative Oncology. 2022. 20. 1. 109-117 ...
Ewings sarcoma is introduced and explained for patients and practitioners with patient stories and support. ... Obata K, Hiraga H, Nojima T, Yoshida MC, Abe S.Molecular characterization of the genomic breakpoint junction in a t(11;22) ... 2. The Sarcoma Universe. 3. Sarcoma Centers. 4. Sarcoma Treatment. 5. Clinical Trials for Sarcoma. ... Ewings sarcoma is one of more than 50 kinds of sarcoma. Each kind is rare, yet all together sarcomas affect hundreds of ...
Yoshida H, Omatsu K, Ueland FR, Kelley JL, Karabakhtsian RG, Roman LD. Characterizing sarcoma dominance pattern in uterine ... Significance of histologic pattern of carcinoma and sarcoma components on survival outcomes of uterine carcinosarcoma. Ann ... Yoshida M, Hakam A, Machida H, Mhawech-Fauceglia P, Ueda Y, Yoshino K, Kajiwara H, Hasegawa K, Yasuda M, Miyake TM, Moriya T, ... Yoshida M, Hakam A, Machida H, Mhawech-Fauceglia P, Ueda Y, Yoshino K, Kajiwara H, Hasegawa K, Yasuda M, Miyake TM, Moriya T, ...
... suggested that these proteins have antitumoral activity against Yoshida ascites sarcoma in rats (4) and enhance the immune ...
... and cachexia induced in rats by either the Yoshida ascites hepatoma (34) or sarcoma (35) and in mice by the MAC16 tumor (20) is ... has been suggested to be crucial for enhanced protein catabolism in skeletal muscles of rats bearing the Yoshida sarcoma (34). ...
Zeng ZJ, Johansson E, Hayashi A, Chavali PL, Akrap N, Yoshida T, Kohno K, Izumi H, Funa K.. Biol Open. 2012 Jun 15;1(6):527-35. ... Fused in sarcoma (FUS) interacts with the cytolinker protein plectin: implications for FUS subcellular localization and ... FET fusion oncoproteins interact with BRD4 and SWI/SNF chromatin remodelling complex subtypes in sarcoma. Mol Oncol. doi: ...
Role of the Prognostic Nutritional Index in Patients With Soft-tissue Sarcoma YUMI MATSUYAMA, TOMOKI NAKAMURA, KEISUKE YOSHIDA ...
Experimentally induced neoplasms of CONNECTIVE TISSUE in animals to provide a model for studying human SARCOMA. ... triethyleneiminebenzoquinone and radiation separately and in various combinations with Yoshida sarcoma, carcinoma Walker and ... Sarcoma, Experimental; Experimental Sarcomas; Sarcomas, Experimental; Engelbreth-Holm-Swarm Sarcoma; Jensen Sarcoma; Sarcoma, ... 09/01/1986 - "The effect of transplantation of rat tumours Jensen sarcoma, sarcoma 45, sarcoma M-1, as well as of inoculation ...
I. Biochemical changes occurring in sensitive and resistant strains of the Yoshida ascites sarcoma following chemotherapy ... of alkylating drugs on growth inhibition and cell size in sensitive and resistant strains of the Yoshida ascites sarcoma ...
Yoshida A et. al. Am J Surg Pathol. 2012;36(7):993-9. ... It acts as a valuable marker for Ewing sarcoma, with a ... NKX2.2 (Neuroendocrine & Ewings Sarcoma Marker) [NX2/1422R]. Monoclonals Primary Antibodies Rabbit Monoclonals Recombinant ... More recently, NKX2.2 protein was identified as a target of EWS-FLI-1, the fusion protein specific to Ewing sarcoma, and was ... Formalin-fixed, paraffin-embedded human Ewing's Sarcoma stained with NKX2.2 Rabbit Recombinant Monoclonal Antibody (NX2/ ...
YOSHIDA (Sarcoma Cells). 1 Z80641. Z80641. CHEMBL614254. 791T Cell Line. 1 Z80647. Z80647. CHEMBL613103. 833K Cell Line. 1 ...
Setsu N, Yoshida A, Takahashi F, et al. Histological analysis suggests an invasion-independent metastatic mechanism in alveolar ... Alveolar soft-part sarcoma: can MRI help discriminating from other soft-tissue tumors? A study of the French sarcoma group[J]. ... Alveolar soft part sarcoma: a single-center 26-patient case series and review of the literature[J]. Sarcoma, 2012, 2012: 907179 ... Alveolar soft part sarcoma: clinical presentation, treatment, and outcome in a series of 13 patients[J]. J Chin Med Assoc, 2018 ...
Yoshida M, Torigoe S, Ikeue K, Yamada M. 2002. Neutralizing antibody responses to human herpesviruses 6 and 7 do not cross- ... Abstract: Kaposis sarcoma-associated herpesvirus (KSHV) is the infectious etiologic agent associated with Kaposis sarcoma (KS ... Kaposis sarcoma-associated herpesvirus (KSHV) is the infectious etiologic agent associated with Kaposis sarcoma (KS), primary ... Reduced levels of neutralizing antibodies to Kaposi sarcoma-associated herpesvirus in persons with a history of Kaposi sarcoma ...
Yoshida A, Tsuta K, Ohno M, Yoshida M, Narita Y, et al. (2014) STAT6 immunohistochemistry is helpful in the diagnosis of ... Arber DA, Kandalaft PL, Mehta P, Battifora H (1993) Vimentin-negative epithelioid sarcoma. The value of an immunohistochemical ... Kitamura Y, Akiyama T, Hirose S, Yoshida K (2012) Optic nerve sheath solitary fibrous tumor. Acta Neurochir 154: 633-635. ... Reactivity with hemangiopericytoma, solitary fibrous tumor, synovial sarcoma, and meningioma but rarely with sarcomatoid ...
32 Davis AM , BellRS, BadleyEM, YoshidaK, WilliamsJI. Evaluating functional outcome in patients with lower extremity sarcoma. ... Davis AM , BellRS, BadleyEM, YoshidaK, WilliamsJI. Evaluating functional outcome in patients with lower extremity sarcoma. Clin ... The presence of erosive changes and extensive soft-tissue infiltration may also lead to the suspicion of soft-tissue sarcoma or ... Greater Manchester and Oswestry Soft Tissue Sarcoma Service (GMOSS), RJAH Orthopaedic Hospital, Oswestry, Shropshire SY10 7AG, ...
Urinary Bladder Rhabdomyosarcoma (Sarcoma Botryoides) in a Young Newfoundland Dog. Mitsuru KUWAMURA, Hiroshi YOSHIDA, Jyoji ... Yumiko YOSHIDA, Motoharu MIYAMURA, Seizo HAMANO, Mitsutoshi YOSHIDA. Article type: FULL PAPER. Subject area: Theriogenology. ...
Yoshida H,Broaddus R,Cheng W,Xie S,Naora H. MA5-11883 was used in immunocytochemistry to study deregulation of the HOXA10 ... Primary gastric histiocytic sarcoma in a dog--a case report.. Journal of veterinary medicine. A, Physiology, pathology, ... Low-grade sarcoma in classical seminoma - the first case reported.. International journal of clinical and experimental ... The Ewings Sarcoma Family of Tumors of Urinary Bladder: A Case Report and Review of the Literature. ...
Soft tissue sarcomas (STS) of the forearm are rare. We aim to assess their oncological and functional outcomes. We ... Muramatsu K, Ihara K, Yoshida K, Tominaga Y, Hashimoto T, et al. Musculoskeletal sarcomas in the forearm and hand: standard ... Soft tissue sarcomas (STS) of the forearm are rare, accounting for only 3-7% of all sarcomas [1,2,3,4,5,6]. Several reports ... Nakata, E., Fujiwara, T., Kunisada, T. et al. Results of resection of forearm soft tissue sarcoma. J Orthop Surg Res 18, 599 ( ...
Tsuyoshi H, Yoshida Y. Molecular biomarkers for uterine leiomyosarcoma and endometrial stromal sarcoma. Cancer Sci. 2018;109(6 ... The most common subtypes of uterine sarcoma are leiomyosarcoma (ULMS), low-grade endometrial stromal sarcoma, and high-grade ... Uterine sarcomas are sporadic mesenchymal neoplasms, and its related research is less than other malignant tumors. Because of ... ULMS is the most common histological subtype of uterine sarcoma originating in the smooth muscles of the myometrium. Because ...
Myeloid sarcoma (MS), also known as chloroma, is an extramedullary manifestation of malignant primitive myeloid cells. ... Kawamoto K, Miyoshi H, Yoshida N, Takizawa J, Sone H, Ohshima K. Clinicopathological, cytogenetic, and prognostic analysis of ... Myeloid sarcoma (MS), also known as granulocytic sarcoma or chloroma, is a solid extramedullary tumor originating from ... Twenty-three patients had 2 or more localizations resulting in overall 183 different lesions of Myeloid sarcoma in 26 different ...
Kuwamura M, Yoshida H, Yamate J, Kotani T, Ohashi F, Sakuma S. Urinary bladder Rhabdomyosarcoma (Sarcoma Botryoides) in a young ... cytological assessment of sarcomas can be challenging. In up to 40% of people diagnosed initially with cardiac sarcoma, the ... People with cardiac sarcomas also have a poor prognosis. It depends on the type, size, location and, above all, on the ... Sarcoma: concordance between initial diagnosis and centralized expert review in a population-based study within three european ...

No FAQ available that match "sarcoma yoshida"